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Abstract
Background: The pathophysiology of insulin resistance-induced hypertension and hyperlipidemia might entail
differences in dementia risk in cases with hypertension and hyperlipidemia without prior diabetes mellitus (DM).
This study investigated whether incident hypertension, incident hyperlipidemia, or both, increased the dementia
risk in patients with and without DM.
Methods: A nationwide retrospective cohort study was conducted. The study sample was obtained from the
National Health Insurance Research Database. We enrolled 10,316 patients with a new diagnosis of DM between
2000 and 2002 in the DM cohort. For the same period, we randomly selected 41,264 patients without DM in the
non-DM cohort (matched by age and sex at a 1:4 ratio with the DM cohort). Both cohorts were then separately
divided into four groups on the basis of incident hypertension or incident hyperlipidemia status.
Results: In total, 51,580 patients aged between 20 and 99 years were enrolled. The dementia risk was higher in the DM
cohort than in the non-DM cohort (adjusted hazard ratio (HR) = 1.47, 95% confidence interval (CI) = 1.30–1.67, p < 0.001).
In the DM cohort, the dementia risk in patients with both hypertension and hyperlipidemia did not significantly increase
compared with that in those without hypertension and hyperlipidemia (p = 0.529). Similar results were observed in those
with either hypertension (p = 0.341) or hyperlipidemia (p= 0.189). In the non-DM cohort, patients with both hypertension
and hyperlipidemia had a higher dementia risk (adjusted HR = 1.33, 95% CI = 1.09–1.63, p= 0.006). The results remained
largely unchanged in patients with only hypertension (adjusted HR = 1.22, 95% CI = 1.05–1.40, p = 0.008). However, the
dementia risk did not increase significantly in patients with only hyperlipidemia (p= 0.187).
Conclusions: The development of hypertension, hyperlipidemia, or both, following a diagnosis of incident diabetes is
secondary to diabetes onset and likely mediated through insulin resistance associated with diabetes, which does not
further accentuate dementia risk. DM itself (i.e., the systemic influence of hyperglycemia) might be the main driver of
increased dementia risk.
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Background
The exact pathogenesis underlying dementia remains
elusive. Cardiovascular risk factors including diabetes
mellitus (DM), hypertension, and hyperlipidemia are
believed to be associated with dementia risk [1, 2]. In
addition, the contribution of insulin resistance to these
cardiovascular risk factors has been identified [3, 4]. The
relationship between DM and dementia risk might be
explained by the potential mechanism of insulin resist-
ance [5, 6] that might be influenced by hyperglycemia
[7]. Furthermore, patients with DM often present
concomitant hypertension and dyslipidemia [8, 9].
Previous studies have reported an association of DM
[10–13] and hypertension [14–16] with an elevated
dementia risk. However, the association between hyper-
lipidemia and dementia remains debatable [17, 18].
These studies have been unable to determine whether
the dementia risk is attributable to factors such as DM,
hypertension, and hyperlipidemia. In addition, the devel-
opment of DM, hypertension, and hyperlipidemia might
share a common mechanism of insulin resistance [19],
which initially presents as hyperglycemia [7]. Moreover,
previous studies have not investigated the dementia risk
associated with the sequence of occurrence of cardiovas-
cular risk factors, especially of insulin resistance that is
expressed DM [18, 20, 21].
The pathophysiology of insulin resistance-induced
hypertension and hyperlipidemia might entail differ-
ences in dementia risk in cases with hypertension and
hyperlipidemia without prior DM. In patients with
diabetes, previously reported data indicate that insulin
resistance might lead to the development of hyperten-
sion [22], which also contributes to elevated plasma
triglyceride levels [23]. However, in patients without
DM, hypertension and hyperlipidemia could be attrib-
uted to excess sodium consumption [24] and nutri-
tional factors [25], respectively.
Therefore, we conducted a nationwide population-
based cohort study up to a 10-year follow-up period
to investigate whether patients with incident DM have
a higher dementia risk. Furthermore, the possible
dementia risk effect in development of hypertension,
hyperlipidemia, or both, was examined in patients
with incident diabetes.
Methods
Study design and data source
The data used in this retrospective cohort study were
obtained from the Longitudinal Health Insurance
Database 2005 (LHID2005), a subset of the National
Health Insurance Research Database (NHIRD). The
NHIRD, maintained by the National Health Research
Institutes (NHRI), contains the claims data of beneficiaries
enrolled in the Taiwan National Health Insurance (NHI)
program, which was implemented in 1995 and covers
approximately 99% of the 23 million residents of Taiwan.
The NHRI compiles the claims data in the NHIRD for
research purposes. All original claims data are anon-
ymized and encrypted before being released to re-
searchers. In addition, researchers who wish to use the
NHIRD and its data subsets must sign a written agree-
ment declaring that they have no intention to obtain infor-
mation that could potentially violate patient privacy.
The LHID2005 contains the claims data of 1,000,000
beneficiaries randomly selected from the Registry of
Beneficiaries of the NHIRD in 2005. The claims data
include information related to outpatient visits, hospital
admissions, and detailed prescriptions. Furthermore,
according to the NHRI, the distribution of age, sex, and
average insurance amount do not differ significantly
between the LHID2005 and NHIRD.
The disease diagnoses in this study were defined
according to the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM)
codes. The diagnostic accuracy of diseases has been vali-
dated in the NHIRD [26, 27]. The prescribed drugs were
identified according to the definition from the Anatomical
Therapeutic Chemical (ATC) codes. This study was evalu-
ated and approved by the Institutional Review Board of
Taipei Medical University and Shin Kong Wu Ho-Su
Memorial Hospital.
Study sample
We identified patients who received a new diagnosis
of DM (ICD-9-CM 250) between 1 January 2000 and
31 December 2002 and included them in the DM
cohort. The first outpatient or inpatient visit for the
DM diagnosis during the study period was considered
as the index date. Patients without DM were
randomly selected at a 1:4 ratio and were included in
the non-DM cohort.
To investigate the effect of incident hypertension
(ICD-9-CM 401–405), incident hyperlipidemia (ICD-9-
CM 272), or both, on dementia risk, we divided the two
cohorts into the following four groups: patients with
both hypertension and hyperlipidemia; those with only
hypertension; those with only hyperlipidemia; and those
without hypertension or hyperlipidemia. In both cohorts,
hypertension and hyperlipidemia diagnoses were ob-
served only following the index date during the follow-
up period. To eliminate the influence of immortal time
bias, the index date was set as the first date when
patients received a diagnosis of hypertension or hyper-
lipidemia when examining the relationship of hyperten-
sion, hyperlipidemia, or both, with dementia risk.
The study endpoint was the subsequent development
of dementia (ICD-9-CM 290.0–290.4, 294.1, 331.0, and
331.1–331.2) [28] from the index date until the end of
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2009. To ensure validity, we excluded patients who did
not have at least three ambulatory visits or one inpatient
visit for the dementia diagnosis.
Moreover, we excluded patients who were younger
than 20 years or older than 99 years, those with missing
information regarding sex and insurance amount, and
those with a history of DM and dementia. In addition, to
investigate the effect of incident hypertension or hyper-
lipidemia on dementia after DM diagnosis, patients who
had received a diagnosis of hypertension and hyperlipid-
emia before the index date were excluded. Moreover, to
reduce the misclassification of patients who had received
a diagnosis of DM, hypertension, or hyperlipidemia, we
excluded those who did not meet the following criteria:
(1) at least three ambulatory visits; or (2) at least one
inpatient visit; or (3) at least one outpatient visit and at
least one prescription for antidiabetic (ATC A10),
antihypertensive (ATC C02–C03 and C07–C09), or
antihyperlipidemic drugs (ATC C10).
Ultimately, 10,316 patients were enrolled in the DM
cohort. The same exclusion criteria were applied to
the non-DM cohort, and ultimately 41,264 patients
without DM matched by age (±1 year) and sex at a
1:4 ratio with the DM cohort were enrolled in the
non-DM cohort. A total of 51,580 patients were in-
cluded for the final analysis. A flowchart of patient
selection is presented in Fig. 1.
Confounders
The confounders in this study were age, sex, insurance
amount, and associated comorbidities. Baseline charac-
teristics for age, sex, and insurance amount were
obtained from the claims records at the index date. The
presence of the following comorbidities was determined
using diagnosis codes within 1 year before the index
date: coronary heart disease (CHD; ICD-9-CM
410–414), stroke (ICD-9-CM 430–438), kidney disease
(ICD-9-CM 580–589), atrial fibrillation (ICD-9-CM
427.3), depression (ICD-9-CM 296.2–296.3, 300.4, and
311), anxiety (ICD-9-CM 300.0, 300.2–300.3, 308.3, and
309.81 ), heart failure (ICD-9-CM 428), alcoholism
(ICD-9-CM 303 and 305.0), chronic obstructive pulmon-
ary disease (COPD; ICD-9-CM 490–496), and obesity
(ICD-9-CM 278, 278.0, 278.00, and 278.01). The vari-
ables of insurance amount and COPD were used as
proxies for socioeconomic status and smoking status, re-
spectively [29]. In addition, these covariates were
adjusted in the statistical models.
Statistical analysis
For the statistical analysis, SAS Version 9.4 for Windows
(SAS Institute Inc., Cary, NC, USA) was used. Continu-
ous variables are expressed as the mean and standard
deviation, and dichotomous variables are expressed as
the frequency and percentage. The Mann–Whitney U
Fig. 1 Flowchart of patient selection. DM diabetes mellitus, HPL hyperlipidemia, HTN hypertension, LHID2005 Longitudinal Health Insurance Database 2005
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test and chi-square test were performed to investigate
the distribution of the sample characteristics and comor-
bidities among the various groups. The dementia-free
survival rate was estimated using the Kaplan–Meier
method with the examination of the log-rank test. First,
dementia risk was evaluated between the DM and
non-DM cohorts through Cox proportional hazards
regression models with hazard ratios (HRs) and 95%
confidence intervals (CIs). Moreover, multivariate Cox
proportional hazards regression models were used to
examine the effect of DM on dementia after adjustment
for potential confounders. In addition, in both the
cohorts, we examined the effect of incident hypertension
or hyperlipidemia on dementia risk. Moreover, the pro-
portions of antihypertensive or antihyperlipidemic drug
prescriptions were compared between the DM and non-
DM cohorts. Furthermore, we performed a sensitivity
analysis by using Cox proportional hazards regression to
assess the robustness of our study results by 1) adjusting
confounders without heart-related diseases and stroke,
and 2) analyzing patients aged between 40 and 80 years.
A p value of less than 0.05 was considered significant.
Results
In total, 51,580 patients aged between 20 and 99 years
were enrolled. We observed 333 dementia events during
89,100.55 person-years in the DM cohort and 981
dementia events during 395,250.15 person-years in the
non-DM cohort. The incidence rate of dementia was
37.37 and 24.82 per 10,000 person-years in the DM and
non-DM cohorts, respectively. In the DM cohort, the
percentages of type I and type II DM were 1.2% and
98.8%, respectively.
The proportion of comorbidities was significantly
higher in the DM cohort than in the non-DM cohort
(Table 1). The Kaplan–Meier analysis revealed that the
dementia-free survival rate was significantly lower in
the DM cohort than in the non-DM cohort (p <
0.001, log-rank test; Fig. 2). The Cox proportional
hazards regression model revealed that the DM co-
hort had a significantly higher dementia risk than the
non-DM cohort (crude HR = 1.54, 95% CI = 1.36–1.74,
p < 0.001). After adjustment for confounders, the de-
mentia risk remained significantly higher in the DM
cohort than in the non-DM cohort (adjusted HR = 1.47,
95% CI = 1.30–1.67, p < 0.001; Table 2).
The distributions of age (p < 0.001), sex (p = 0.002), in-
surance amount (p < 0.001), and comorbidities of CHD
(p < 0.001), stroke (p < 0.001), atrial fibrillation (p =
0.011), depression (p = 0.001), heart failure (p < 0.001),
and COPD (p < 0.001) differed significantly among the
four groups according to status of hypertension or
hyperlipidemia in the DM cohort (data not shown). In
the unadjusted model, the dementia risk in patients with
Table 1 Distribution of sample characteristics according to
diabetes mellitus





Age (years), mean (SD) 53.00 (12.59) 53.00 (12.59) 1.000
Sex, n (%) 1.000
Male 5472 (53) 21888 (53)
Female 4844 (47) 19376 (47)
Coronary heart disease, n (%) <0.001
Yes 592 (5.7) 819 (2)
No 9724 (94.3) 40445 (98)
Stroke, n (%) <0.001
Yes 356 (3.5) 519 (1.3)
No 9960 (96.5) 40745 (98.7)
Kidney disease, n (%) <0.001
Yes 444 (4.3) 455 (1.1)
No 9872 (95.7) 40809 (98.9)
Atrial fibrillation, n (%) <0.001
Yes 39 (0.4) 52 (0.1)
No 10277 (99.6) 41212 (99.9)
Depression, n (%) <0.001
Yes 181 (1.8) 361 (0.9)
No 10135 (98.2) 40903 (99.1)
Anxiety, n (%) <0.001
Yes 411 (4) 649 (1.6)
No 9905 (96) 40615 (98.4)
Heart failure, n (%) <0.001
Yes 134 (1.3) 132 (0.3)
No 10182 (98.7) 41132 (99.7)
Alcoholism, n (%) <0.001
Yes 40 (0.4) 49 (0.1)
No 10276 (99.6) 41215 (99.9)
COPD, n (%) <0.001
Yes 972 (9.4) 2357 (5.7)
No 9344 (90.6) 38907 (94.3)
Obesity, n (%) <0.001
Yes 79 (0.8) 17 (0)
No 10237 (99.2) 41247 (100)
Insurance amount, n (%) <0.001
<20000 NTD 7489 (72.6) 28545 (69.2)
20000–40000 NTD 1602 (15.5) 6949 (16.8)
≧40000 NTD 1225 (11.9) 5770 (14)
COPD chronic obstructive pulmonary disease, NTD New Taiwan Dollar, SD
standard deviation
aTested using the Mann–Whitney U test and the chi-square test
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both hypertension and hyperlipidemia did not increase
significantly compared with that in patients without
hypertension and hyperlipidemia (p = 0.539); however, a
significantly higher risk was observed in patients with
only hypertension (crude HR = 2.35, 95% CI = 1.72–3.22,
p < 0.001), whereas there was a significantly lower risk in
patients with only hyperlipidemia (crude HR = 0.40, 95%
CI = 0.25–0.64, p < 0.001). Furthermore, after adjustment
for age, sex, insurance amount, and comorbidities, the
dementia risk in patients with both hypertension and
hyperlipidemia did not increase significantly compared
to that in patients with neither hypertension nor
Fig. 2 Dementia-free survival rate in patients with and without diabetes mellitus (DM), as estimated using the Kaplan–Meier method (log-rank
test; p < 0.001)
Table 2 Incident hypertension and incident hyperlipidemia in prediction of dementia
Event PYs Crude model Adjusted modelb
HR 95% CI p valuea HR 95% CI p valuea
DM cohort 333 89,101 1.54 1.36–1.74 <0.001 1.47 1.30–1.67 <0.001
Both HTN and HPL 126 24,637 1.10 0.81–1.51 0.539 0.90 0.66–1.24 0.529
HTN only 124 11,533 2.35 1.72–3.22 <0.001 1.17 0.85–1.60 0.341
HPL only 25 13,785 0.40 0.25–0.64 <0.001 0.72 0.45–1.17 0.189
No HTN and HPL 58 12,932 1.00 1.00
Non-DM cohort 981 395,250 1.00 1.00
Both HTN and HPL 130 24,367 2.79 2.28–3.41 <0.001 1.33 1.09–1.63 0.006
HTN only 418 59,711 3.70 3.21–4.25 <0.001 1.22 1.05–1.40 0.008
HPL only 31 12,468 1.31 0.90–1.89 0.154 1.28 0.89–1.85 0.187
No HTN and HPL 402 217,378 1.00 1.00
CI confidence interval, COPD chronic obstructive pulmonary disease, DM diabetes mellitus, HTN hypertension, HPL hyperlipidemia, HR hazard ratio, PYs person-years
aTested using Cox proportional hazards regression
bAdjusted for age, sex, coronary heart disease, stroke, kidney disease, atrial fibrillation, depression, anxiety, heart failure, alcoholism, chronic obstructive pulmonary
disease, obesity, and insurance amount
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hyperlipidemia (p = 0.529). However, the nonsignificant
results were observed in patients with only hypertension
(p = 0.341) or hyperlipidemia (p = 0.189; Table 2), while
it maintained the same direction as reported in the un-
adjusted model.
The results differed between the DM and non-DM
cohorts. All sample characteristics differed signifi-
cantly among the four groups in the non-DM cohort
(all p < 0.05), except for alcoholism (p = 0.854) and
obesity (p = 0.084; data not shown). As presented in
Table 2, patients with both hypertension and hyperlip-
idemia exhibited a significantly higher dementia risk
than those with neither hypertension nor hyperlipid-
emia (crude HR = 2.79, 95% CI = 2.28–3.41, p < 0.001).
The dementia risk was also significantly higher in pa-
tients with only hypertension (crude HR = 3.70, 95%
CI = 3.21–4.25, p < 0.001). However, patients with only
hyperlipidemia did not exhibit a significantly higher
dementia risk (crude HR = 1.31, 95% CI = 0.90–1.89,
p = 0.154). The results did not change markedly after
adjustment for confounders.
The proportions of antihypertensive or antihyperlipi-
demic treatment were examined between the DM and
non-DM cohorts in patients with hypertension, hyperlip-
idemia, or both. No significant difference was observed
in the percentage of combined prescriptions for treating
hypertension and hyperlipidemia between the DM and
non-DM cohort in patients with both hypertension
and hyperlipidemia (99.13% and 99.62%, respectively;
p = 0.805). In addition, the proportion of medications
taken for treating hypertension in diabetic and nondi-
abetic patients in the hypertension-only group did not
reach statistical significance (97.43% and 98.26%,
respectively; p = 0.738). Similar results were obtained
for the proportion of antihyperlipidemic drug use in
patients with only hyperlipidemia between the dia-
betic and nondiabetic groups (69.89% and 70.32%,
respectively; p = 0.863).
The sensitivity analysis results were comparable with the
total sample, not only in the adjusted model that excluded
the confounders of heart-related diseases and stroke but
also in patients aged from 40 to 80 years. As shown in
Table 3, the adjusted HR for dementia risk was nonsignifi-
cant in patients with hypertension, hyperlipidemia, or both
compared with individuals with neither hypertension
nor hyperlipidemia in patients with DM. In the non-
Table 3 Sensitivity analysis of incident hypertension and incident hyperlipidemia in prediction of dementia
Event PYs Adjusted model
HR 95% CI p valuea
Adjusted confounders without heart related diseases and stroke
DM cohort Both HTN and HPLb 126 24,637 0.90 0.65–1.24 0.514
HTN onlyb 124 11,533 1.16 0.85–1.59 0.359
HPL onlyb 25 13,785 0.71 0.44–1.15 0.161
No HTN and HPL 58 12,932 1.00
Non-DM cohort Both HTN and HPLb 130 24,367 1.35 1.10–1.66 0.004
HTN onlyb 418 59,711 1.23 1.07–1.42 0.004
HPL onlyb 31 12,468 1.29 0.90–1.87 0.170
No HTN and HPL 402 217,378 1.00
Age between 40 and 80 years (n = 43,320)
DM cohort Both HTN and HPLc 119 22,358 0.86 0.61–1.22 0.396
HTN onlyc 112 10,409 1.12 0.80–1.58 0.513
HPL onlyc 25 10,657 0.75 0.46–1.23 0.255
No HTN and HPL 48 8709 1.00
Non-DM cohort Both HTN and HPLc 127 23,444 1.33 1.07–1.64 0.009
HTN onlyc 356 55,729 1.23 1.06–1.44 0.008
HPL onlyc 28 11,257 1.19 0.81–1.75 0.380
No HTN and HPL 354 166,275 1.00
CI confidence interval, COPD chronic obstructive pulmonary disease, DM diabetes mellitus, HTN hypertension, HPL hyperlipidemia, HR hazard ratio, PYs person-years
aTested using Cox proportional hazards regression
bAdjusted for age, sex, kidney disease, depression, anxiety, alcoholism, chronic obstructive pulmonary disease, obesity, and insurance amount
cAdjusted for age, sex, coronary heart disease, stroke, kidney disease, atrial fibrillation, depression, anxiety, heart failure, alcoholism, chronic obstructive pulmonary
disease, obesity, and insurance amount
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DM cohort, an increased dementia risk was observed
in patients with both hypertension and hyperlipidemia
(p < 0.05) and hypertension only (p < 0.05), but not in
those with hyperlipidemia only (p > 0.05).
Discussion
In this population-based retrospective cohort study,
patients with incident DM exhibited a higher dementia
risk during the average follow-up of 9.39 years. Although
incident hypertension and incident hyperlipidemia
increased the dementia risk in the non-DM cohort, the
development of hypertension, hyperlipidemia, or both,
following an incident diabetes diagnosis is secondary to
diabetes onset and likely mediated through insulin resist-
ance associated with diabetes, which does not further
accentuate dementia risk. Moreover, we observed that,
among the cardiovascular risk factors, DM itself (i.e., the
systemic influence of hyperglycemia) might be the main
driver of increased dementia risk.
Several studies have investigated the effect of DM on de-
mentia in various populations worldwide [10, 12, 18, 30–32].
Our results demonstrated an association between DM and
dementia risk. This finding was consistent with those of pre-
vious studies. The data source and research design used in a
2015 Taiwanese study by Kuo et al. were similar to those
used in our study, except for examining the sequence of the
occurrence of comorbidities [18]. However, their results were
not comparable to our results because they did not
adequately investigate the relationship among DM, hyperten-
sion, and hyperlipidemia. First, although they divided the
diabetic cohort into insulin and noninsulin users, they did
not use antidiabetic medications to define the DM cohort.
By contrast, we defined strict criteria for including patients
in the DM cohort, which included patients who received a
DM diagnosis at least three times during outpatient visits or
at least once during inpatient visits or had at least one
outpatient visit and at least a prescription for antidiabetic
drugs. Second, they identified comorbidities only at the base-
line. Therefore, the sequence of the occurrence of comorbidi-
ties such as DM, hypertension, and hyperlipidemia remained
unclear. Third, they analyzed the confounding effects of only
specific variables, such as age and sex, and did not consider
the effect of other comorbidities, which affected the estima-
tion of adjusted hazard ratios. Finally, they did not evaluate
the effect of hypertension or hyperlipidemia on dementia
following the DM diagnosis. By contrast, we simultaneously
investigated the effect of hypertension and hyperlipidemia to
examine the pathogenesis underlying the dementia risk in
patients with and without DM.
The exact pathogenic mechanism underlying dementia
is complex and remains unclear. Our results demon-
strated that the dementia risk in the DM cohort did not
increase or decrease significantly in patients with hyper-
tension, hyperlipidemia, or both. Recent studies have
reported that insulin resistance might be a key factor for
increasing cognitive impairment risk [10, 33]. Insulin re-
sistance in the brain impairs insulin signaling, which can
influence the regulation of food intake, body weight,
reproduction, and learning and memory [34]. Disrupted
insulin signaling has been associated with the develop-
ment of Alzheimer’s disease [35]. It can increase senile
plaques along with the deposition of amyloid beta
protein and neurofibrillary tangles because of tau phos-
phorylation [36]. These mechanisms might accelerate
the pathology of Alzheimer’s disease [33]. Insulin resist-
ance is associated with a higher risk of type 2 DM
and increases the risk of dyslipidemia and hyperten-
sion [19, 37]. In addition, insulin resistance might be
the key etiological link to type 2 DM [38]. The patho-
genesis underlying type 2 DM is characterized by
insulin resistance and impaired insulin secretion [39].
Moreover, previous data have suggested that the
development of hypertension and hyperlipidemia in
patients with DM were induced by insulin resistance
[22, 23]. As mentioned previously, insulin resistance
is impaired by sustained hyperglycemia [7]. Therefore,
we considered DM to be the main driver of the
underlying dementia risk through hyperglycemia
(which induces insulin resistance) rather than hyper-
tension or hyperlipidemia.
Previous studies have reported more efficient progno-
sis among patients who receive medications for treating
hypertension or hyperlipidemia [40, 41]. However, we
observed that nondiabetic patients with hypertension
and hyperlipidemia still exhibited a higher dementia risk
than those without hypertension and hyperlipidemia
after adjustment for potential confounders, although
most individuals received related prescriptions. In the
present study, the results reveal that the percentage of
antihypertensive or antihyperlipidemic drugs used in the
DM cohort was not significantly higher in patients with
hypertension, hyperlipidemia, or both, compared with
those in the non-DM cohort. Although the dementia
risk varied between patients with and without DM, the
medication proportions of the two cohorts were similar.
Thus, this finding should not be influenced whether
prescriptions are given to treat hypertension or hyperlip-
idemia. Otherwise, despite the high proportion of
patients receiving drug prescriptions, the NHIRD does
not provide detailed information regarding the medica-
tion taken. Notably, the substantial concordance for
medication use between claims data and patient self-
reports has been validated [42].
We observed an inverse association - although not al-
ways statistically significant - between hyperlipidemia
and risk of dementia in the DM cohort which was not
replicated in the non-DM one. It could be speculated
that hyperlipidemia secondary to DM may exert a
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specific biological effect on the risk of dementia. A sig-
nificantly lower dementia risk was observed in patients
with diabetes and only hyperlipidemia in the crude
model, whereas no significant effect was observed after
adjustment for related confounders. This effect still
maintained the same direction even if the significances
were different before and after adjustment, which was in
the absence of a significant interaction effect with all
confounders. Furthermore, the lower crude HR of de-
mentia in hyperlipidemia-only patients who received sta-
tins for at least 60 days was significant at 0.20 (p < 0.001)
compared to those with neither hypertension nor hyper-
lipidemia in the DM cohort, but not in those who
received statins for less than 60 days (HR = 0.56, p = 0.255)
and in patients without statin and other antihyperlipidemic
therapy (HR = 0.53, p = 0.057). After adjustment, only
hyperlipidemia patients taking statins for at least
60 days were associated with reduced dementia risk
(HR = 0.41, p = 0.042), while other groups showed an
insignificant inverse association (HR = 1.19 and 1.02,
respectively; all p > 0.05). In addition, a mediating
effect of statins between hyperlipidemia and dementia
risk was found (p < 0.05) in diabetic patients. A previ-
ous study reported that statin use might decrease the
risk of Alzheimer’s disease [43], which might support
the data interpretation. Further studies are needed to
evaluate the role of hyperlipidemia and related treat-
ments with risk of dementia in diabetic patients.
Our study has several limitations that should be
addressed. First, information regarding several risk
factors for dementia could not be obtained from the
claims data, including information regarding cholesterol
levels, family history, APOE, body mass index, and phys-
ical activity. In addition, the confounders extracted from
medical records might be underestimated, in which the
proportion of obesity was lower. This might lead to a
residual effect when the association of exposures with
outcomes is considered. Second, all disease information
retrieved in this study was based on ICD-9-CM codes.
Moreover, because the LHID2005 contains the claims
data of beneficiaries enrolled in the NHI program,
potential ascertainment bias and misclassification bias
may be present. However, we used a strict criterion to
identify the exposure and outcome to reduce the uncer-
tainty of diagnosis. In addition, the NHI program covers
approximately 99% of the residents of Taiwan and has
good generalizability; therefore, the resulting misclassifi-
cation bias is likely to be nondifferential. Third, surveil-
lance bias might occur in patients with and without DM
when detecting incident hypertension or hyperlipidemia.
However, the percentages of antihypertensive or antihy-
perlipidemic prescriptions in each group were compar-
able between the two cohorts. Finally, mild cognitive
impairment and dementia severity cannot be identified
from the NHIRD. We included all dementia types; there-
fore, the results of different dementia severities could
not be determined. However, the most common cause of
dementia in Taiwan is Alzheimer’s disease, the diagnosis
of which is relatively homogeneous [44]. In addition, pa-
tients with dementia before the index date were ex-
cluded in order to examine the causality.
Conclusions
The dementia risk was higher in the DM cohort than in
the non-DM cohort during the average follow-up of
9.39 years. DM itself (i.e., the systemic influence of hyper-
glycemia) might be the main driver of increased dementia
risk. The development of hypertension, hyperlipidemia, or
both, following an incident diabetes diagnosis is secondary
to diabetes onset and likely mediated through the insulin
resistance associated with diabetes, which does not
further accentuate dementia risk. However, hyperten-
sion and hyperlipidemia increased the dementia risk
in the non-DM cohort. Future studies should examine
the pathogenesis underlying dementia. The prevention
of these comorbidities during diabetes remains clinic-
ally crucial and might reduce the dementia risk.
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